DHCNL — Diversified Healthcare Trust

Summary of DHCNL Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $379.6 million
• Adjusted EBITDAre: $72.4 million
• Normalized FFO: $21.8 million ($0.09 per share)
• Consolidated NOI Growth: 31.3% year-over-year
• SHOP NOI: $38.3 million for Q4, up 27.6% year-over-year; full-year SHOP NOI was $139.3 million, at the high end of guidance.
• Same Property Occupancy: Increased 90 basis points year-over-year to 82.4%.
• Average Monthly Rate: Increased by 5.8%.
• Net Debt to Adjusted EBITDA: Reduced from 11.2x to 8.1x.
• Liquidity: Approximately $255 million, including $105 million in unrestricted cash.

2. Strategic Updates and Business Highlights

• Completed over $1.4 billion in capital markets activity, focusing on financing and asset sales.
• Transitioned 116 communities to seven operators, enhancing operational oversight and local expertise.
• Renovated over 30 communities and identified opportunities to reopen closed skilled nursing wings, potentially adding 500 SHOP units with a mid-teens ROI.
• Medical Office and Life Science portfolio saw a 3.8% year-over-year increase in same-property cash basis NOI, with consolidated occupancy rising to 91.2%.

3. Forward Guidance and Outlook

• 2026 Guidance for NOI:
  • SHOP segment: $175 million to $185 million
  • Medical Office and Life Science: $94 million to $98 million
  • Triple net leased senior living communities: $28 million to $30 million
• Adjusted EBITDAre for 2026: Expected between $290 million and $305 million.
• Normalized FFO: Projected at $0.52 to $0.58 per share.
• Continued focus on operational improvements and strategic investments to drive shareholder value.

4. Bad News, Challenges, or Points of Concern

• The transition of operators may cause temporary disruptions, although Q4 showed improvement.
• Anticipated decline in NOI for Medical Office and Life Science due to the sale of properties contributing $12.3 million in 2025.
• Potential challenges in maintaining occupancy and revenue growth amid competitive pressures and market conditions.
• The company is cautious about external acquisitions, focusing on internal operational improvements instead.

5. Notable Q&A Insights

• Management emphasized a focus on organic growth through operational enhancements rather than new acquisitions.
• The reopening of closed wings is expected to provide significant ROI, but costs and timelines remain to be fully defined.
• Operators are expected to improve margins as they stabilize their cost structures post-transition.
• The company is not prioritizing dividend changes at this time, focusing instead on operational growth and financial stability.
• January and February trends appear promising, with no significant negative impacts from seasonal flu.

This summary encapsulates the key points from the earnings call, providing a clear overview of DHCNL's financial performance, strategic direction, and outlook while addressing potential challenges and insights from the Q&A session.